atai Life Sciences, based in Berlin, pioneers drug development for mental health disorders with a focus on psychedelics. The company secured $312 million cash plus $175 million non-dilutive debt, extending its runway into 2025. Under CEO Srini G. Rao, atai Life Sciences has reprioritized its clinical pipeline, achieved four key R&D milestones, and anticipates multiple proof-of-concept readouts within two years.

‌